Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
2,522 results
  • Current management of low-grade gliomas. [Journal Article]
  • COCurr Opin Neurol 2016 Sep 26
  • Hottinger AF, Hegi ME, Baumert BG
  • CONCLUSIONS: Regarding molecular prognostic factors, IDH wild-type LGGs have the worst prognosis, independent of therapy, whereas patients with mutated IDH, codeleted 1p/19q LGGs fared best regarding progression-free survival (PFS). In high-risk LGGs, PFS is similar regardless of whether patients have been treated with radiation or TMZ. In the second trial, patients who were treated with combination radiation and chemotherapy showed significant longer overall survival.
  • Chemotherapy for Adults with Malignant Glioma: A Systematic Review and Network Meta-analysis. [Journal Article]
  • TNTurk Neurosurg 2015 Aug 25
  • Wen W, Guang S, … Bo Z
  • CONCLUSIONS: The results of this analysis suggest that bevacizumab plus temozolomide combination therapy is not significantly more effective than temozolomide alone in improving survival of glioma patients. Moreover, bevacizumab was associated with higher hematologic toxicities. Based on the results, we suggest that bevacizumab should be used with caution in glioma patients. Additional randomized controlled trials are required to confirm this finding.
New Search Next